Stanford University
300 Pasteur Drive, Stanford, CA 94304
USA
Presenter: Edgar Engleman, MD
Professor, Pathology and Immunology & Rheumatology
Stanford University
Please note: This event will be held in Alway M106
Dr. Engleman is Professor of Pathology and Medicine at Stanford University School of Medicine, where he oversees the Stanford Blood Center and his own immunology research group. An editor of numerous scientific journals and the inventor of multiple patented technologies, Dr. Engleman has authored more than 250 publications in medical and scientific journals and has trained more than 200 graduate students and postdoctoral fellows.
He has co-founded a number of biopharmaceutical companies including Cetus Immune, Genelabs, National Medical Audit and Dendreon. He is the lead inventor of the technology underlying Provenge, Dendreon’s cancer vaccine, which was shown to extend life for patients with metastatic prostate cancer with remarkably few side effects. Provenge is the first active immunotherapeutic agent to be approved by the FDA (in 2010).
Dr. Engleman currently serves on the boards of several private biotechnology companies. He received his B.A. from Harvard University and his M.D. from Columbia University School of Medicine.
Dr. Engleman’s research is directed at understanding the role of the cellular immune system in cancer and other life threatening conditions and in evaluating the potential to manipulate immune cells for the treatment of these diseases. They have been particularly interested in dendritic cells (DC) and their “first generation” methods for isolating and arming human DC with tumor antigens provided the basis for the Sipuleucel-T (aka Provenge) vaccine that was approved by the FDA in 2010 for the treatment of advanced prostate cancer. More recently, the lab has been studying functionally distinct DC populations, including DC that promote tumor formation and metastases, as well as DC that can induce anti-tumor immunity.